Great Point Partners LLC Gracell Biotechnologies Inc. Transaction History

Great Point Partners LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.83 - $4.9 $4.78 Million - $8.27 Million	-1,688,390 Reduced 74.44%	579,667 $1.67 Million
Q2 2023 Aug 14, 2023	SELL	$1.45 - $6.07 $1.28 Million - $5.37 Million	-885,149 Reduced 28.07%	2,268,057 $8.64 Million
Q1 2023 May 15, 2023	BUY	$1.8 - $2.5 $2.14 Million - $2.98 Million	1,190,807 Added 60.68%	3,153,206 $5.86 Million
Q4 2022 Feb 14, 2023	BUY	$2.08 - $3.96 $3.15 Million - $5.99 Million	1,513,350 Added 337.01%	1,962,399 $4.51 Million
Q3 2022 Nov 14, 2022	BUY	$2.08 - $5.15 $934,021 - $2.31 Million	449,049 New	449,049 $1.45 Million

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.